Compounding pharmacies caught in counterfeit controversy [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Compounding pharmacies have increasingly been at the centre of safety concerns around the legitimacy and credibility of medications marketed and sold, especially obesity drugs. Novo Nordisk's Ozempic (semaglutide), for example, has been making headlines worldwide, increasingly becoming synonymous with prompting significant weight loss. Compounding is the practice of customising medications for individual patients, and it is subject to specific US Food and Drug Administration (FDA) regulations. Amid recent news relating to compounding pharmacy safety concerns, consumer concerns swirl as to whether the presence of obesity drugs like Ozempic in compounding pharmacies poses risks to patient health. With Ozempic growing in prevalence not only in the pharma sphere, but also the broader zeitgeist, its presence has intensified the focus on medications released to address obesity and Type 2 diabetes. In 2024, the FDA responded and released guidance on medications containing semaglutide ma
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- WeightWatchers CEO Sima Sistani is leaving the company [Yahoo! Finance]Yahoo! Finance
- PFE vs. NVO: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's Wegovy-Fueled Gains Fading as Analyst Doubts Grow [Yahoo! Finance]Yahoo! Finance
- She took Ozempic, now she can't eat without vomiting. Lawsuit claims the drug made her ill [USA TODAY]USA TODAY
- Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/16/24 - Form 6-K
- NVO's page on the SEC website